BioSpace News Archive

Overlake Medical Center & Clinics this week became the first hospital in the Pacific Northwest region to successfully treat patients for atrial fibrillation utilizing a safer, innovative and minimally invasive treatment technique known as pulsed field ablation.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Kronos Bio, Inc. announced a plan to optimize its resource allocation, restructure, and extend runway to focus resources on key programs in the Company’s pipeline, including the ongoing phase 1/2 study of KB-0742 following the review of additional positive preliminary safety and efficacy data.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) today announced its financial results for the fourth quarter ended December 31, 2023, and provided corporate updates.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2023.

Immersion Corporation, a leading developer and provider of technologies for haptics, reported financial results for the fourth quarter and full year ended December 31, 2023.

Covalon Technologies Ltd., an advanced medical technologies company, announced the results of the matters voted upon at its Fiscal 2023 Annual Meeting of Shareholders held March 6, 2024.

Evogene Ltd. today announced its financial results for the fourth quarter and full-year period ending December 31, 2023.

Bruker Corporation (Nasdaq: BRKR) is pleased to announce the successful closing of its acquisition of Chemspeed Technologies AG, a leading Swiss provider of automated laboratory R&D and QC workflow solutions.

Upstream Bio Initiates a Phase 2 Clinical Trial of Verekitug (UPB-101) in Severe Asthma and Doses First Patients.